<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769235</url>
  </required_header>
  <id_info>
    <org_study_id>CLBG 1210</org_study_id>
    <nct_id>NCT01769235</nct_id>
  </id_info>
  <brief_title>Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide)Gel, 1.2%/2.5% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety and efficacy profiles of Taro
      Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya®
      (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% and to demonstrate the superior
      efficacy of the two active formulations over that of the vehicle in the treatment of acne
      vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change in inflammatory lesion counts.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change in non-inflammatory lesion counts.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response of &quot;success&quot;.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of subjects at week 12 with a clinical response of &quot;success&quot; is defined as an Investigators Global Assessment score that is at least 2 grades less than the baseline assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1215</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acanya® Gel, 1.2%/2.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of test product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of test product (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%</intervention_name>
    <description>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).</description>
    <arm_group_label>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acanya® Gel, 1.2%/2.5%</intervention_name>
    <description>Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).</description>
    <arm_group_label>Acanya® Gel, 1.2%/2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of test product</intervention_name>
    <description>Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).</description>
    <arm_group_label>Vehicle of test product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing and able to provide written informed consent/assent for the study.

          -  Be 12 to 40 years of age, inclusive. A subject may be of either sex and any
             race/ethnicity.

          -  Have a clinical diagnosis of facial acne vulgaris with 25 or greater non-inflammatory
             lesions and 20 or greater inflammatory lesions and no more than 2 nodulocystic
             lesions.

          -  Have a baseline Investigator's Global Assessment of acne severity grade of 2, 3 or 4
             on a severity scale of 0 to 4.

          -  Be willing and able to understand and comply with the requirements of the study, apply
             the study medication as instructed, refrain from use of all other topical acne
             medication and topical antibiotics during the 12-week treatment period, return for the
             required treatment period visits, comply with therapy prohibitions, and able to
             complete the study.

          -  Be in general good health and free from any clinically significant disease, other than
             acne vulgaris, that might interfere with the study evaluations.

          -  Female subjects of childbearing potential must have a negative urine pregnancy test
             amd must be willing to use a medically accepted method of contraception during the
             study.

        Exclusion Criteria:

          -  Presence of more than 2 facial nodulocystic lesions (i.e., nodules and cysts).

          -  Current diagnosis of acne conglobata, acne fulminans, or secondary acne.

          -  Presence of active cystic acne, or polycystic ovarian syndrome.

          -  History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or
             antibiotic-associated colitis.

          -  Presence of any other facial skin condition that might interfere with acne vulgaris
             diagnosis and/or assessment.

          -  Excessive facial hair that would interfere with diagnosis or assessment of acne
             vulgaris.

          -  History of unresponsiveness to topical clindamycin phosphate and/or benzoyl peroxide
             therapy.

          -  Start or change of dose of estrogens or hormonal treatment 3 months prior to baseline
             or throughout the study.

          -  Use of medicated make-up throughout the study and significant change in the use of
             consumer products within 30 days of study entry and throughout the study.

          -  Use of any of the following treatments more recently than the indicated washout period
             prior to visit 1/day 1; need or intent to continue to use any of the following
             treatments during the study: oral retinoids or therapeutic Vitamin A supplements of
             greater than 10,000 units/day; systemic steroids; systemic antibiotics; systemic
             treatment for acne vulgaris ; systemic anti-inflammatory or immunosuppressive agents
             (NSAID use is allowed on an as-needed basis but for no more than 7 days of consecutive
             use, low dose aspirin is allowed if on a stable dose for at least 30 days);
             Spironolactone; use on the face of cryodestruction or chemodestruction, dermabrasion,
             photodynamic therapy, acne surgery, intralesional steroids, x-ray therapy; topical
             retinoids; topical steroids; topical anti-acne medications; topical anti-inflammatory
             agents; topical antibiotics; medicated cleansers; use of tanning booths, sun lamps,
             sunbathing or excessive exposure to the sun; antipruritics, including antihistamines.

          -  History of hypersensitivity or allergy to clindamycin phosphate, benzoyl peroxide, and
             /or any ingredient in the study medication.

          -  Females who are pregnant, breastfeeding, intending to become pregnant during the
             study, or who do not agree to use an acceptable form of birth control during the
             study.

          -  Consumption of excessive alcohol, abuse of drugs, or a condition that could compromise
             the subject's ability to comply with study requirements.

          -  Any clinically significant condition or situation other than acne vulgaris that would
             interfere with the study evaluations or optimal participation.

          -  Use of any investigational drugs within 30 days prior to visit 1/day 1.

          -  Participation in any other clinical study in the 30 days prior to signing the informed
             consent form.

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Symbio CRO</last_name>
    <role>Study Chair</role>
    <affiliation>http://symbioresearch.com/</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Clindamycin Phosphate and Benzoyl Peroxide Gel</keyword>
  <keyword>Acanya® Gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

